ONUREG Trademark

Trademark Overview

On Tuesday, September 25, 2018, a trademark application was filed for ONUREG with the United States Patent and Trademark Office. The USPTO has given the ONUREG trademark a serial number of 88131315. The federal status of this trademark filing is REGISTERED as of Tuesday, November 23, 2021. This trademark is owned by Celgene Corporation. The ONUREG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer
onureg

General Information

Serial Number88131315
Word MarkONUREG
Filing DateTuesday, September 25, 2018
Status700 - REGISTERED
Status DateTuesday, November 23, 2021
Registration Number6569697
Registration DateTuesday, November 23, 2021
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 5, 2019

Trademark Statements

Description of MarkThe mark consists of overlapping purple circles with 4 dots with white centers, the first two and last dots are in blue and white and the second dot is yellow and white dots with the word "ONUREG" in blue to the right.
Goods and ServicesPharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer
Indication of Colors claimedThe color(s) blue, purple, white and yellow is/are claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 2, 2018
Primary Code005
First Use Anywhere DateTuesday, September 1, 2020
First Use In Commerce DateTuesday, September 1, 2020

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Tuesday, November 23, 2021REGISTERED-PRINCIPAL REGISTER
Thursday, October 21, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, October 20, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, October 12, 2021STATEMENT OF USE PROCESSING COMPLETE
Friday, October 8, 2021USE AMENDMENT FILED
Friday, October 8, 2021TEAS STATEMENT OF USE RECEIVED
Friday, October 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 7, 2021SOU EXTENSION 5 GRANTED
Monday, October 4, 2021SOU EXTENSION 5 FILED
Monday, October 4, 2021TEAS EXTENSION RECEIVED
Friday, May 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 6, 2021SOU EXTENSION 4 GRANTED
Friday, April 2, 2021SOU EXTENSION 4 FILED
Wednesday, May 5, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 5, 2021NOTICE OF REVIVAL - E-MAILED
Monday, April 5, 2021EXTENSION RECEIVED WITH TEAS PETITION
Monday, April 5, 2021PETITION TO REVIVE-GRANTED
Monday, April 5, 2021TEAS PETITION TO REVIVE RECEIVED
Thursday, September 17, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 15, 2020SOU EXTENSION 3 GRANTED
Tuesday, September 15, 2020SOU EXTENSION 3 FILED
Tuesday, September 15, 2020TEAS EXTENSION RECEIVED
Monday, September 14, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, September 14, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, September 14, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, September 14, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 14, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, September 14, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 3, 2020SOU EXTENSION 2 GRANTED
Tuesday, March 3, 2020SOU EXTENSION 2 FILED
Tuesday, March 3, 2020TEAS EXTENSION RECEIVED
Wednesday, August 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 5, 2019SOU EXTENSION 1 GRANTED
Monday, August 5, 2019SOU EXTENSION 1 FILED
Monday, August 5, 2019TEAS EXTENSION RECEIVED
Tuesday, April 2, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 14, 2019APPLICANT SUPPLIED CHANGES/CORRECTIONS AFTER PUB APPROVAL NOT ENT
Friday, February 8, 2019ASSIGNED TO PETITION STAFF
Tuesday, February 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 5, 2019PUBLISHED FOR OPPOSITION
Friday, January 25, 2019TEAS POST PUBLICATION AMENDMENT RECEIVED
Wednesday, January 16, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 3, 2019ELECTRONIC RECORD REVIEW COMPLETE
Friday, December 28, 2018ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Wednesday, December 26, 2018ASSIGNED TO LIE
Tuesday, December 4, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, December 3, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 3, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 3, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 30, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 30, 2018NON-FINAL ACTION E-MAILED
Friday, November 30, 2018NON-FINAL ACTION WRITTEN
Friday, November 30, 2018ASSIGNED TO EXAMINER
Wednesday, October 3, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, October 2, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 28, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

onureg pharmaceutical preparations treatment blood disease cancer system modulate namely cytokine